

Brilliant Violet 421™ anti-human CD200R

Catalog # / Size: 2246565 / 25 tests
2246570 / 100 tests

Clone: OX-108

Isotype: Mouse IgG1, κ


Immunogen: Human CD200R full length fusion protein

Reactivity: Human, Non-human primate

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD3 (clone UCHT1) PE and CD200R (clone OX-108) Brilliant Violet 421™ (left) or Mouse IgG1, κ Brilliant Violet 421™ isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application References: 1. Wright GJ, *et al.* 2003. *J. Immunol.* 171:3034.

Description: CD200R, also known as OX2R, is a membrane glycoprotein with up to 70% of its weight derived from N-linked glycosylation. CD200R is expressed primarily by monocytes and neutrophils, but also by other leukocytes including T cells and mast cells. The interaction between CD200 and CD200R may contribute to pathways that suppress and limit macrophage induced inflammatory damage in tissues.

Antigen References: 1. Wright GJ, *et al.* 2003. *J. Immunol.* 171:3034.
2. Gorczyński R, *et al.* 2004. *J. Immunol.* 172:7744.

